Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)

ARS Pharmaceuticals' Finished Goods history spans 2 years, with the latest figure at $7.3 million for Q1 2025.

  • For Q1 2025, Finished Goods changed N/A year-over-year to $7.3 million; the TTM value through Mar 2025 reached $7.3 million, changed N/A, while the annual FY2024 figure was $5.2 million, N/A changed from the prior year.
  • Finished Goods for Q1 2025 was $7.3 million at ARS Pharmaceuticals, up from $5.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $7.3 million in Q1 2025 and bottomed at $5.2 million in Q4 2024.